Verve Therapeutics Inc (NASDAQ: VERV) on Monday, plunged -7.73% from the previous trading day, before settling in for the closing price of $3.62. Within the past 52 weeks, VERV’s price has moved between $3.46 and $9.31.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Over the past five-year period, the growth rate of yearbook sales for the company of the Healthcare sector was 136.15%. The company achieved an average annual earnings per share of -13.49%. With a float of $66.12 million, this company’s outstanding shares have now reached $88.76 million.
Considering the fact that the conglomerate employs 274 people, you should pay attention to its efficiency factor. In terms of profitability, gross margin is 84.37%, operating margin of -707.23%, and the pretax margin is -613.51%.
Verve Therapeutics Inc (VERV) Insider Activity
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Verve Therapeutics Inc is 25.54%, while institutional ownership is 69.90%. The most recent insider transaction that took place on Apr 02 ’25, was worth 40,761. In this transaction Chief Executive Officer of this company sold 9,822 shares at a rate of $4.15, taking the stock ownership to the 346,686 shares. Before that another transaction happened on Apr 02 ’25, when Company’s Chief Administrative Officer sold 2,777 for $4.15, making the entire transaction worth $11,525. This insider now owns 17,420 shares in total.
Verve Therapeutics Inc (VERV) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around -13.49% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 5.30% during the next five years compared to -42.43% drop over the previous five years of trading.
Verve Therapeutics Inc (NASDAQ: VERV) Trading Performance Indicators
Verve Therapeutics Inc (VERV) is currently performing well based on its current performance indicators. A quick ratio of 12.65 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 9.17.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.35, a number that is poised to hit -0.65 in the next quarter and is forecasted to reach -2.69 in one year’s time.
Technical Analysis of Verve Therapeutics Inc (VERV)
Compared to the last year’s volume of 1.52 million, its volume of 2.5 million showed improvement in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 7.43%. Additionally, its Average True Range was 0.50.
During the past 100 days, Verve Therapeutics Inc’s (VERV) raw stochastic average was set at 3.87%, which indicates a significant decrease from 8.30% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 72.46% in the past 14 days, which was lower than the 102.33% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $6.51, while its 200-day Moving Average is $5.95. Nevertheless, the first resistance level for the watch stands at $3.61 in the near term. At $3.89, the stock is likely to face the second major resistance level. The third major resistance level sits at $4.14. If the price goes on to break the first support level at $3.08, it is likely to go to the next support level at $2.83. Should the price break the second support level, the third support level stands at $2.55.
Verve Therapeutics Inc (NASDAQ: VERV) Key Stats
Market capitalization of the company is 296.58 million based on 88,796K outstanding shares. Right now, sales total 32,330 K and income totals -198,710 K. The company made 13,080 K in profit during its latest quarter, and -50,040 K in sales during its previous quarter.
